ACAD
Acadia Pharmaceuticals
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NASDAQ: ACAD
- PEG Ratio
Based on the latest data from Jul 2, 2026, ACAD's PEG ratio sits at 0.19. This metric combines a PE of 11.65 with an earnings growth rate of 61.6%. Relative to the 0.12 average from the past 4 quarters, the PEG ratio has surged by 58%.
ACAD PEG ratio history
Looking at the past two years, ACAD's PEG ratio has settled around 0.17 on average. At 0.19, today's PEG ratio sits 12% higher than its historical average. Within the past two years, the Jun 2024 quarter saw the highest PEG reading at 0.72. At 0, the Mar 2025 quarter represented the lowest PEG ratio in this timeframe.
Acadia Pharmaceuticals PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.17 | 11.51 | 69.3% |
| 2024 | 0.03 | 13.39 | 470.3% |
| 2023 | N/A | N/A | 72.4% |
| 2022 | N/A | N/A | -27.6% |
| 2021 | N/A | N/A | 41.3% |
| 2020 | N/A | N/A | -11.9% |
| 2019 | N/A | N/A | 17.5% |
| 2018 | N/A | N/A | 17.8% |
| 2017 | N/A | N/A | -0.9% |
| 2016 | N/A | N/A | -43.6% |
| 2015 | N/A | N/A | -71.6% |
| 2014 | N/A | N/A | -115.9% |
| 2013 | N/A | N/A | -15.8% |
| 2012 | N/A | N/A | 13.6% |
| 2011 | N/A | N/A | -212.8% |
Acadia Pharmaceuticals PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.16 | 9.98 | 61.6% |
| Dec 2025 | 0.17 | 11.51 | 69.3% |
| Sep 2025 | 0.13 | 13.59 | 101.3% |
| Jun 2025 | 0.02 | 16.1 | 644.4% |
| Mar 2025 | 0 | 12.04 | 13,900% |
| Dec 2024 | 0.03 | 13.39 | 470.3% |
| Sep 2024 | 0.11 | 19.72 | 184.8% |
| Jun 2024 | 0.72 | 90.28 | 126.1% |
| Mar 2024 | N/A | N/A | 98.9% |
| Dec 2023 | N/A | N/A | 72.4% |
| Sep 2023 | N/A | N/A | 31.9% |
| Jun 2023 | N/A | N/A | 45.7% |
| Mar 2023 | N/A | N/A | 31.6% |
| Dec 2022 | N/A | N/A | -27.6% |
| Sep 2022 | N/A | N/A | -12.5% |
ACAD average PEG ratio chart
ACAD's PEG ratio today is above the 3, 5 and 10-year averages.
PEG comparison
Acadia Pharmaceuticals's PEG of 0.19 is lower than the Healthcare sector and the industry average. In comparison with the Healthcare sector average of 0.6, Acadia Pharmaceuticals's PEG is 68% lower.
ACAD EPS growth
ACAD Price vs fair value
ACAD PEG vs peers
ACAD carries a PEG ratio lower than that of peer stocks LLY and BMY.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| ACAD Acadia Pharmaceuticals Inc | 0.19 | $4.45B |
| LLY ELI LILLY & Co | 0.34 | $1.14T |
| BMY Bristol Myers Squibb Co | 0.49 | $118.71B |
| VNDA Vanda Pharmaceuticals Inc | N/A | $373.44M |
| PFE Pfizer Inc | N/A | $138.61B |
| JNJ Johnson & Johnson | N/A | $633.19B |
Frequently asked questions
What is Acadia Pharmaceuticals's PEG ratio?
Based on Jul 2, 2026 data, ACAD shows a PEG ratio of 0.19.
What is the 3-year average PEG ratio for Acadia Pharmaceuticals (ACAD)?
ACAD shows a 3-year average PEG ratio of 0.17.
What is the 5-year average PEG ratio for Acadia Pharmaceuticals (ACAD)?
ACAD shows a 5-year average PEG ratio of 0.17.
What is the highest PEG ratio for ACAD?
ACAD's PEG ratio topped out at 0.72 during the Jun 2024 quarter - the highest in two years.
How does the current PEG ratio for ACAD compare to its historical average?
ACAD currently has a PEG ratio 12% above its 2-year average.
Why is Acadia Pharmaceuticals's PEG ratio so low?
The 0.19 PEG ratio for ACAD reflects robust earnings growth outpacing the current valuation.
How is ACAD's PEG ratio calculated (Acadia Pharmaceuticals PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jul 2, 2026, Acadia Pharmaceuticals carries a PE ratio of 11.65. Earnings grew at 61.6% over the TTM period ending Mar 2026. Applying the formula, this yields a PEG ratio of 0.19. PEG RATIO(0.19) = PE RATIO(11.65) / EPS GROWTH(61.6%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.